Lepu Biopharma Co., Ltd. (HKG:2157)

Market Cap	9.80B
Revenue (ttm)	767.54M
Net Income (ttm)	-194.17M
Shares Out	1.80B
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,083,000
Average Volume	7,674,713
Open	5.25
Previous Close	5.16
Day's Range	5.18 - 5.54
52-Week Range	2.26 - 10.50
Beta	-0.16
RSI	43.19
Earnings Date	Mar 27, 2026

About Lepu Biopharma

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of first-in class and best-in-class drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 498
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2157

Financial Performance

In 2024, Lepu Biopharma's revenue was 367.79 million, an increase of 63.21% compared to the previous year's 225.35 million. Losses were -411.38 million, 1761.8% more than in 2023.

Financial numbers in CNY